Insider buying · SEC Form 4

KLRS insider buying

Open-market purchases of Kalaris Therapeutics, Inc. (KLRS) stock by its own executives, directors and 10% owners — every Form 4 buy of $250K or more that SPX Lens's daily insider scan has recorded, newest first.

1insider buy on record
$1.18Mbought in total
1insider
0by CEOs, CFOs and other chiefs
May 26, 2026latest scan with a buy

Every recorded buy

ScanInsiderValueSharesAvg priceTypeFiled
May 26, 2026Srinivas AkkarajuDirector (via Samsara Opportunity Fund L.P.)$1.18M244,300$4.83AddedMay 22, 2026
Form 4 ↗
Privately negotiated transfer at $4.83/share between Samsara Opportunity Fund and Samsara BioCapital (both Akkaraju-controlled); transaction code P; now $4.92 (+1.9%). Post-Q1 results. Samsara stake reached 56.5%.

Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.

SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →

See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.

Open the live chartOpen in the Stocks tab

© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.